Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
Clinical Psychopharmacology and Neuroscience
;
: 37-40, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-53119
ABSTRACT
OBJECTIVE:
We investigated the effects of duloxetine on the plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor (BDNF) in 64 patients with major depressive disorder (MDD).METHODS:
Major depressive episode was diagnosed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) according to the DSM-IV text revision (DSM-IV-TR) criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). Blood sampling and clinical evaluation were performed on days 0, 28, and 56.RESULTS:
Duloxetine treatment for 8 weeks significantly increased the plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels but not the homovanillic acid (HVA) levels in responders with MDD.CONCLUSION:
These results imply that noradrenaline plays an important role in alleviating depressive symptoms.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Plasma
/
Norepinefrina
/
Fator Neurotrófico Derivado do Encéfalo
/
Manual Diagnóstico e Estatístico de Transtornos Mentais
/
Depressão
/
Transtorno Depressivo Maior
/
Cloridrato de Duloxetina
/
Ácido Homovanílico
Tipo de estudo:
Guia de Prática Clínica
/
Pesquisa qualitativa
Limite:
Humanos
Idioma:
Inglês
Revista:
Clinical Psychopharmacology and Neuroscience
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS